uniQure (QURE) Net Cash Flow (2016 - 2026)
uniQure (QURE) posted quarterly Net Cash Flow of $273.8 million for Q2 2026, up 724.15% year-over-year from $33.2 million in Q2 2025, and up 349.83% quarter-over-quarter from $60.9 million in Q1 2026.
uniQure (QURE) Net Cash Flow (2016 - 2026) Analysis & Trends
uniQure's Net Cash Flow history runs 11 years deep, the most recent figure standing at $273.8 million for Q2 2026.
- In Q2 2026, Net Cash Flow rose 724.15% year-over-year to $273.8 million; the TTM figure through Jun 2026 stood at $160.6 million (up 522.15% YoY), while the FY2025 annual figure was -$84.2 million, down 6.23% from the prior year.
- Net Cash Flow for Q2 2026 stood at $273.8 million, up from $60.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $359.0 million in Q2 2023, with the low at -$516.5 million in Q4 2025.
- The 5-year median for Net Cash Flow is -$8.4 million (2022), against an average of -$8.0 million.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow plunged 971.33% in 2022, then jumped 1877.17% in 2023.
- uniQure's Net Cash Flow stood at -$222.3 million in 2022, then jumped by 104.53% to $10.1 million in 2023, then slumped by 954.13% to -$86.0 million in 2024, then slumped by 500.67% to -$516.5 million in 2025, then jumped by 153.01% to $273.8 million in 2026.
- Business Quant data shows QURE's Net Cash Flow at $273.8 million in Q2 2026, $60.9 million in Q1 2026, and -$516.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | uniQure | 3.37 Bn | 3.37 Bn | 5.49 Mn | 273.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 273.80 Mn |
| Jun 30, 2026 | 273.80 Mn |
| Mar 31, 2026 | 60.87 Mn |
| Mar 31, 2026 | 60.87 Mn |
| Dec 31, 2025 | -516.49 Mn |
| Dec 31, 2025 | -516.49 Mn |
| Sep 30, 2025 | 342.42 Mn |
| Sep 30, 2025 | 342.42 Mn |
| Jun 30, 2025 | 33.22 Mn |
| Jun 30, 2025 | 33.22 Mn |
| Mar 31, 2025 | 56.67 Mn |
| Mar 31, 2025 | 56.67 Mn |
| Dec 31, 2024 | -85.99 Mn |
| Dec 31, 2024 | -85.99 Mn |
| Sep 30, 2024 | -41.95 Mn |
| Sep 30, 2024 | -41.95 Mn |
| Jun 30, 2024 | 45.23 Mn |
| Jun 30, 2024 | 45.23 Mn |
| Mar 31, 2024 | 3.41 Mn |
| Mar 31, 2024 | 3.41 Mn |